Naming conventionsThere are several conventions used for naming chiral compounds, all displayed as a prefix before the chemical name of the substance:
- based on the substance's ability to rotate polarized light.
- based on the actual geometry of each enantiomer, with the version synthesized from naturally occurring (+)-glyceraldehyde being considered the D- form.
- based on the actual geometry of each enantiomer, using the Cahn-Ingold-Prelog priority rules to classify the form. Molecules with multiple stereogenic centers will have a corresponding number of letters; e.g. natural (+)-α-tocopherol is R,R,R-α-tocopherol. The (+)- vs. (−)- convention is the only one based on optical properties. The other two conventions are based on the actual geometry of each enantiomer. There is no correspondence between any convention. In nature, many chiral substances are only produced in one optical form, while (most) man-made chiral substances are racemic mixtures. The purity of enantiomers can be determined by optical rotation. More definitions
Enantioselective preparationsSeveral strategies exist for the preparation of enantiopure compounds. This first method is the separation of a racemic mixture into its isomers, a process called chiral resolution. Louis Pasteur in his pioneering work was able to isolate the isomers of tartaric acid because they crystallize from solution as crystals each with a different symmetry. A less common method is by enantiomer self-disproportionation. Another method is chiral pool synthesis: the use of chiral starting materials and maintaining the chirality. In asymmetric synthesis, which includes asymmetric induction, the use of chiral auxiliaries, chiral reagents, and chiral catalysts such as biocatalysts, the reaction of one diastereomer is favored over another. Enantioconvergent synthesis is the synthesis of one enantiomer from a racemic precursor molecule utilizing both enantiomers. Enantiopure medicationsAdvances in industrial chemical processes have made it economical for pharmaceutical manufacturers to take drugs that were originally marketed in racemic form and market the individual enantiomers, each of which may have unique properties. For some drugs, such as zopiclone, only one enantiomer (eszopiclone) is active; the FDA has allowed such once-generic drugs to be patented and marketed under another name [2]. In other cases, such as ibuprofen, it is not economically feasible to isolate a single enantiomer from a racemic mixture or to synthesize just the active one, and therefore a racemic mixture is marketed, with an essentially doubled recommended dose. Examples of racemic mixtures and the corresponding single-enantiomer products that have been marketed include:
Thalidomide is an example of a racemic drug, in which one enantiomer produces a desirable antiemetic effect, whereas the other is toxic and produces a teratogenic side-effect. However, the enantiomers are converted into each other in vivo, so chemical processes cannot be used to mitigate its toxicity. See also
References
| | |||||||||||||||||